Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): Study protocol for a randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Nunn, Andrew J ^a   Rusen, I D ^b   Van Deun, Armand ^b,c   Torrea, Gabriela ^c   Phillips, Patrick P J ^a   Chiang, Chen Yuan ^b,d   Squire, S Bertel ^e   Madan, Jason ^f   Meredith, Sarah K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Multi drug resistant tuberculosis; Multicenter randomized trial; Non inferiority; Shorter treatment duration

Indexed keywords

CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; TUBERCULOSTATIC AGENT; QUINOLONE DERIVATIVE;

ARTICLE; BANGLADESH; CONTROLLED STUDY; CROSS RESISTANCE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; ECONOMIC EVALUATION; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCREENING; SINGLE DRUG DOSE; SOCIAL STATUS; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; METHODOLOGY; MICROBIOLOGY; TIME FACTOR; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; BANGLADESH; CLINICAL PROTOCOLS; CLOFAZIMINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FLUOROQUINOLONES; HUMANS; ISONIAZID; KANAMYCIN; PROTHIONAMIDE; PYRAZINAMIDE; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84907022895     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-353     Document Type: Article

References (29)

1. World Health Organization Global Tuberculosis Report 2013 2013, Geneva: World Health Organization, World Health Organization.
2. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012, 9:e1001300. 10.1371/journal.pmed.1001300, 3429397, 22952439.
3. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update 2011, Geneva: World Health Organization, World Health Organization.
4. Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010, 182:684-692. 10.1164/rccm.201001-0077OC, 20442432.
5. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161. 10.1016/S1473-3099(09)70041-6, 19246019.
6. World Health Organization Global tuberculosis programme treatment of tuberculosis: guidelines for national programmes 1997, Geneva: World Health Organization, World Health Organization.
7. Bignall J, Lind A, Rist N. A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis. Bull Int Union Tuberc 1969, 42:7.
8. Gumbo T, Louie A, Deziel M, Parsons L, Salfinger M, Drusano G. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004, 190:1642-1651. 10.1086/424849, 15478070.
9. Bulatovic V, Wengenack N, Uhl J, Hall L, Roberts G, Cockerill F, Rusnak F. Oxidative stress increases susceptibility of Mycobacterium tuberculosis to isoniazid. Antimicrob Agents Chemother 2002, 46:2765-2771. 10.1128/AAC.46.9.2765-2771.2002, 127408, 12183226.
10. Van Deun A. 9-month standardized MDR-TB regimen in Bangaldesh: an update. Proceedings of the 43rd World Conference on Lung Health Kuala Lumpur Malaysia, 13-17 November 2012, Int J Tuberc Lung Dis 2012, 16 (12) supplement 1: S42-43
11. Aung KJM, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL. Successful " 9-month Bangladesh regimen" for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014, 18:1180-1187.
12. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993, 328:527-532. 10.1056/NEJM199302253280802, 8426619.
13. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006, 10:605-612.
14. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA, . Gatifloxacin for TB OFLOTUB study team A Phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:128-138(111). Gatifloxacin for TB OFLOTUB study team.
15. Feng Y, Liu S, Wang Q, Wang L, Tang S, Wang J, Lu W. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLoS One 2013, 8:e55292. 10.1371/journal.pone.0055292, 3562191, 23383320.
16. Mitchison DA, Keyes AB, Edwards EA, Ayuma P, Byfield SP, Nunn AJ. Quality control in tuberculosis bacteriology. 2. The origin of isolated positive cultures from the sputum of patients in four studies of short course chemotherapy in Africa. Tubercle 1980, 61:135. 10.1016/0041-3879(80)90002-1, 6777920.
17. Fox W, Ellard G, Mitchison D. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999, 3:S231-S279.
18. Bloss E, Kuksa L, Holtz T, Riekstina V, Skripconoka V, Kammerer S, Leimane V. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010, 14:275-281.
19. Malla P, Kanitz EE, Akhtar M, Falzon D, Feldmann K, Gunneberg C, Jha SS, Maharjan B, Prasai MK, Shrestha B. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. PLoS One 2009, 4:e8313. 10.1371/journal.pone.0008313, 2794372, 20041140.
20. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007, 29:374-379. 10.1016/j.ijantimicag.2006.11.011, 17241772.
21. Altin T, Ozcan O, Turhan S, Ozdemir AO, Akyurek O, Karaoguz R, Guldal M. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol 2007, 23:907-908. 10.1016/S0828-282X(07)70850-4, 2651372, 17876386.
22. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002, 62:1649-1671. 10.2165/00003495-200262110-00006, 12109926.
23. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lonnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J 2014, 43:1763-1775. 10.1183/09031936.00193413, 4040181, 24525439.
24. Gospodarevskaya E, Tulloch O, Bunga C, Ferdous S, Jonas A, Islam S, Rahman M, Hussain M, Haque M, Egwaga S, Gardiner E, PrayGod G, Islam M, Mann G, Wells W, Squire S. Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens. Int J Tuberc Lung Dis 2014, 18:810-817. 10.5588/ijtld.13.0391, 24902557.
25. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMC Med 2010, 8:18. 10.1186/1741-7015-8-18, 2860339, 20334633.
26. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012, 308:2594-2604. 10.1001/jama.2012.87802, 23268518.
27. Cochrane AL. Effectiveness and Efficiency: Random Reflections on Health Services 1971, London: Nuffield Provincial Hospitals Trust.
28. Kuaban C. 12-month standardized MDR-TB regimen: experience in Cameroon. Symposium 28. Advances in the treatment of MDR-TB: current recommendations, short course MDR-TB regimens and new drugs. Proceedings of the 43rd World Conference on Lung Health Kuala Lumpur Malaysia, 13-17 November 2012, Int J Tuberc Lung Dis 2012, 16 (12) supplement 1: S43
29. Piubello A, Hassane H, Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, Van Deun A. High cure-rate without relapse of short standardized treatment of multidrug-resistant tuberculosis in Niger. Int J Tuberc Lung Dis 2014, 18:1188-1194.